Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,002 public trials 569 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Active, Not Recruiting

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Local Institution - 102 Scottsdale, Arizona, United States
  • Mayo Clinic Scottsdale, Arizona, United States
  • Local Institution - 107 Little Rock, Arkansas, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
View all 162 locations
View Trial Details
Active, Not Recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Arkansas Little Rock, Arkansas, United States
  • City of Hope Duarte, California, United States
  • UC San Diego Health Moores Cancer Center San Diego, California, United States
  • University of California San Francisco (UCSF) San Francisco, California, United States
View all 106 locations
View Trial Details
Active, Not Recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

NCT06353022

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • CH de la Côte Basque Bayonne, France
  • CHU Caen Caen, France
  • CHRU DIjon Dijon, France
  • Chd Vendee La Roche-sur-Yon, France
View all 19 locations
View Trial Details
Active, Not Recruiting

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

NCT02886065

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Weill Cornell Medical College New York, United States
View Trial Details

Related conditions